Document:

Employment Agreement - John Shannon

 Exhibit 10.14 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (this
“Agreement”) is made and entered into this 20th day of June, 2012 (the “Effective Date”), by and between Durata Therapeutics, Inc., a Delaware corporation (the “Company”), and John Shannon (the
“Executive”). 
 THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings
and intentions: 
 A. The Company desires to continue to retain the Executive as an employee of the Company to carry out
the duties and responsibilities described below, all on the terms and conditions hereinafter set forth, as of the Effective Date. 
 B. The Executive desires to continue such employment by the Company on the terms and conditions set forth in this Agreement as of the Effective Date. 

C. This Agreement shall govern the employment relationship between the Executive and the Company from and after the Effective Date
and, as of the Effective Date, supersedes and negates all previous agreements with respect to such relationship. 
 NOW,
THEREFORE, in consideration of the above recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the
parties hereto agree as follows: 
 1. Retention and Duties. 

1.1 Retention. The Company does hereby engage and employ the Executive for the Period of Employment (as such
term is defined in Section 2) on the terms and conditions expressly set forth in this Agreement. The Executive does hereby accept and agree to such engagement and employment, on the terms and conditions expressly set forth in this
Agreement. 
 1.2 Duties. During the Period of Employment, the Executive shall serve the
Company as the Company’s Chief Commercial Officer and shall have the powers, authorities, duties and obligations of management usually vested in the office of the Chief Commercial Officer of a company of a similar size and similar nature of the
Company, and such other powers, authorities, duties and obligations commensurate with such position as the Company’s Chief Executive Officer (“CEO”) may assign from time to time, all subject to the directives of the CEO and the
corporate policies of the Company as they are in effect from time to time throughout the Period of Employment (including, without limitation, the Company’s business conduct and ethics policies, as they may change from time to time). During the
Period of Employment, the Executive shall report to the CEO. 
 1.3 No Other Employment; Minimum Time Commitment.
During the Period of Employment, the Executive shall (a) devote substantially all of the Executive’s business time, energy and skill to the performance of the Executive’s duties for the Company, (b) perform such duties in a
faithful, effective and efficient manner to the best of the Executive’s abilities and carry out all of the Company’s policies and directives in a manner which will promote and 

  
 - 1 -

 
develop the Company’s best interests, and (c) hold no other employment. The Executive’s service on the boards of directors (or similar body) of other business entities is subject
to the prior written approval of the CEO. The CEO shall have the right to require the Executive to resign from any board or similar body (including, without limitation, any association, corporate, civic or charitable board or similar body) which the
Executive may then serve if the CEO reasonably determines that the Executive’s service on such board or body interferes with the effective discharge of the Executive’s duties and responsibilities to the Company or that any business related
to such service is then in competition with any business of the Company or any of its Affiliates (as such term is defined in Section 5.5), successors or assigns, or could reasonably be expected in the future to be in competition with the
Company. 
 1.4 No Breach of Contract. The Executive hereby represents to the Company that: (a) the execution
and delivery of this Agreement by the Executive and the Company and the performance by the Executive of the Executive’s duties hereunder, do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default
under any other agreement or policy to which the Executive is a party or otherwise bound or any judgment, order or decree to which the Executive is subject; (b) that the Executive is not required to obtain a waiver or consent from any other
Person in order for the Executive to perform the Executive’s duties hereunder; (c) that the Executive has no information (including, without limitation, confidential information and trade secrets) relating to any other Person (as such term
is defined in Section 5.5) which would prevent, or be violated by, the Executive entering into this Agreement or carrying out the Executive’s duties hereunder; (d) the Executive is not bound by any employment, consulting,
non-compete, confidentiality, trade secret or similar agreement with any other Person; and (e) the Executive understands that the Company will rely upon the accuracy and truth of the representations and warranties of the Executive set forth
herein (including, without limitation, the Executive’s curriculum vitae that the Executive provided to the Company prior to the Effective Date) and the Executive consents to such reliance. 

1.5 Location. The Company’s headquarters are currently located in Morristown, New Jersey. The Executive shall be
regularly present at the Company’s headquarters, as such headquarters may be so located from time to time. In addition, the Executive acknowledges and agrees that the Executive may be required to travel from time to time in the course of
performing the Executive’s duties for the Company. 
 2. Period of Employment. The “Period of Employment”
shall be a period of one (1) year commencing on the Effective Date and ending at the close of business on the one year anniversary of the Effective Date (the “Termination Date”); provided, however, that this
Agreement shall be automatically renewed, and the Period of Employment shall be automatically extended for one (1) additional year on the Termination Date and each anniversary of the Termination Date thereafter, unless either party gives
written notice at least ninety (90) days prior to the expiration of the Period of Employment (including any renewal thereof) of such party’s desire to terminate the Period of Employment (such notice to be delivered in accordance with
Section 18). The term “Period of Employment” shall include any extension thereof pursuant to the preceding sentence. Provision of notice that the Period of Employment shall not be extended or further extended, as the case may
be, shall not constitute a breach of this Agreement. Notwithstanding the foregoing, the Period of Employment is subject to earlier termination as provided below in this Agreement. 

  
 - 2 -

 3. Compensation. 
 3.1 Base Salary. During the Period of Employment, the Company shall pay the Executive a base salary (the “Base Salary”), which shall be paid in accordance with the
Company’s regular payroll practices in effect from time to time, but not less frequently than in semi-monthly installments. The Executive’s Base Salary shall be at an annualized rate of Two Hundred Eighty Five Thousand Dollars ($285,000).
The Company’s Board of Directors (the “Board”) (or a committee thereof) shall review the Executive’s rate of Base Salary on an annual basis and may, in the Board’s sole discretion, increase (but not decrease, except in the
event of a broad-based reduction for all employees at the Company) the rate then in effect. 
 3.2
Incentive Bonus. The Executive shall be eligible to receive an incentive bonus for each fiscal year of the Company that occurs during the Period of Employment (“Incentive Bonus”); provided, however, that,
except as provided in Section 5.3, the Executive must be employed by the Company on the last day of a fiscal year in order to be eligible for an Incentive Bonus with respect to that fiscal year (and, if the Executive is not so employed
at such time, in no event, except as expressly provided in Section 5.3, shall the Executive have been considered to have “earned” any Incentive Bonus with respect to the fiscal year in question). The Executive’s target
Incentive Bonus amount (“Target Bonus Amount”) for a particular fiscal year of the Company shall equal thirty-five percent (35%) of the Executive’s Base Salary at the rate in effect for such year; provided,
further, that the Executive’s actual Incentive Bonus amount for a particular fiscal year shall be determined by the Organization and Compensation Committee of the Company’s Board of Directors (the “Committee”) in such
Committee’s sole discretion, based on individual and Company performance objectives established with respect to that particular fiscal year by the Committee in consultation with the CEO and the Executive. The Incentive Bonus, if any, payable
for a particular fiscal year shall be paid to the Executive no later than two and one-half (2 1/2) months following the end of such fiscal year. 
 4. Benefits.

 4.1 Retirement, Health, Welfare and Fringe Benefits. During the Period of Employment, the Executive shall
be entitled to participate in all employee pension, health and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Company to the Company’s employees generally in accordance with the eligibility and
participation provisions of such plans and as such plans or programs may be in effect from time to time. During the period of Employment and at the sole discretion of the Board, the Executive shall be entitled to participate in all of the
Company’s current and future equity incentive plans. 
 4.2 Reimbursement of Business Expenses. The Executive
is authorized to incur reasonable business expenses in carrying out the Executive’s duties for the Company under this Agreement and shall be entitled to reimbursement for all reasonable business expenses the Executive incurs during the Period
of Employment in connection with carrying out the Executive’s duties for the Company, subject to the Company’s expense reimbursement policies and any pre-approval policies in effect from time to time. 

4.3 Vacation and Other Leave. During the Period of Employment, the Executive’s annual rate of vacation accrual shall
be four (4) weeks per year; provided, however, that such vacation shall accrue and be subject to the Company’s vacation policies in effect from time to time. The Executive shall also be entitled to all other holiday and leave
pay generally available to other executives of the Company. 

  
 - 3 -

 5. Termination. 
 5.1 Termination by the Company. The Executive’s employment by the Company, and the Period of Employment, may be terminated at any time by the Company: (a) with Cause (as such term
is defined in Section 5.5); or (b) without Cause; or (c) in the event of the Executive’s death; or (d) in the event that the Board determines in good faith that the Executive has a Disability (as such term is defined
in Section 5.5). 
 5.2 Termination by the Executive. The Executive’s employment by the Company,
and the Period of Employment, may be terminated by the Executive with no less than ninety (90) days advance written notice to the Company (such notice to be delivered in accordance with Section 18). 

5.3 Benefits Upon Termination. If the Executive’s employment by the Company is terminated during the Period of
Employment for any reason by the Company or by the Executive, or upon or following the expiration of the Period of Employment (in any case, the date that the Executive’s employment by the Company terminates is referred to as the
“Severance Date”), the Company shall have no further obligation to make or provide to the Executive, and the Executive shall have no further right to receive or obtain from the Company, any payments or benefits except as follows:

 (a) The Company shall pay the Executive (or, in the event of the Executive’s death, the Executive’s estate) any
Accrued Obligations (as such term is defined in Section 5.5); 
 (b) If, during the Period of Employment, the
Executive’s employment with the Company is terminated by the Company without Cause (and other than due to the Executive’s death or a good faith determination by the Board that the Executive has incurred a Disability), the Executive shall
be entitled to the following benefits: 
 (i) Subject to Section 5.3(b)(ii) below, the Company shall
pay the Executive (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to six (6) months of the Executive’s Base Salary at the annualized rate in effect on the Severance
Date. Such amount is referred to hereinafter as the “Severance Benefit.” Subject to Section 19.1, the Company shall pay the Severance Benefit to the Executive in substantially equal installments in accordance with the
Company’s standard payroll practices over a period of six(6) consecutive months, with the first installment payable in the month following the month in which the Executive’s Separation from Service (as such term is defined in
Section 5.5) occurs. (For purposes of clarity, each such installment shall equal the applicable fraction of the aggregate Severance Benefit. For example, if such installments were to be made on a monthly basis, each installment would
equal one-sixth (1/6th)). 

(ii) The Company shall pay or reimburse the Executive for the Executive’s premiums charged to continue medical coverage pursuant to
the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), at the same or reasonably equivalent medical 

  
 - 4 -

 coverage for the Executive (and, if applicable, the Executive’s eligible
dependents) as in effect immediately prior to the Severance Date, to the extent that the Executive elects such continued coverage; provided, however, that, the Company’s obligation to make any payment or reimbursement pursuant to
this clause (ii) shall, subject to Section 19.1, commence with continuation coverage for the month following the month in which the Executive’s Separation from Service occurs and shall cease with continuation coverage in the
sixth (6th) month following the month in which the
Executive’s Separation from Service occurs (or, if earlier, shall cease upon the first to occur of the Executive’s death, the date the Executive becomes eligible for coverage under the health plan of a future employer, or the date the
Company ceases to offer group medical coverage to its active executive employees or the Company is otherwise under no obligation to offer COBRA continuation coverage to the Executive). To the extent that the Executive elects COBRA coverage, he shall
notify the Company in writing of such election prior to such coverage taking effect and complete any other continuation coverage enrollment procedures the Company may then have in place. 

(c) If, during the Period of Employment, there is a Change in Control and the Executive’s employment with the Company is terminated
by the Company without Cause (and other than due to the Executive’s death or a determination by the Board that the Executive has incurred a Disability), or by the Executive for Good Reason, in each case within two (2) months prior to or
within twelve (12) months following the Change in Control, then the Executive shall be entitled to the following benefits: 
 (i) The Company shall pay the Executive (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to six (6) months of the Executive’s
Base Salary at the annualized rate in effect on the Severance Date. Such amount is referred to hereinafter as the “CIC Severance Benefit.” Subject to Section 19.1, the Company shall pay the CIC Severance Benefit to the
Executive in substantially equal installments in accordance with the Company’s standard payroll practices over a period of six(6) consecutive months, with the first installment payable in the month following the month in which the
Executive’s Separation from Service occurs. (For purposes of clarity, each such installment shall equal the applicable fraction of the aggregate CIC Severance Benefit. For example, if such installments were to be made on a monthly basis, each
installment would equal one-sixth (1/6th). 
 (ii) The Company shall pay or reimburse the Executive for the
Executive’s premiums charged to continue medical coverage pursuant to COBRA, at the same or reasonably equivalent medical coverage for the Executive (and, if applicable, the Executive’s eligible dependents) as in effect immediately prior
to the Severance Date, to the extent that the Executive elects such continued coverage; provided, however, that, the Company’s obligation to make any payment or reimbursement pursuant to this clause (iii) shall, subject to
Section 19.1, commence with continuation coverage for the month following the month in which the Executive’s Separation from Service occurs and shall cease with continuation coverage in the sixth (6th) month following the month in which the Executive’s
Separation from Service occurs (or, if earlier, shall cease upon the first to occur of the Executive’s death, the date the Executive becomes eligible for coverage under the health plan of a future employer, or the date the Company ceases to
offer group medical coverage to its active executive employees or the Company is otherwise under no obligation to offer COBRA continuation coverage to the 

  
 - 5 -

 
Executive). To the extent that the Executive elects COBRA coverage, he shall notify the Company in writing of such election prior to such coverage taking effect and complete any other
continuation coverage enrollment procedures the Company may then have in place. 
 (iii) All outstanding stock options and
other equity compensation awards granted to Executive by the Company shall become fully vested and free from forfeiture restrictions as of the Severance Date. In all other respects, the stock options and other equity compensation awards shall be
governed by the applicable award agreement and plan under which the award was granted. 
 (iv) For the avoidance of doubt, to
the extent that the Executive is entitled to severance payments and benefits under Section 5.3(c), Executive shall not be entitled to severance payments and benefits under Section 5.3(b). 

(d) Notwithstanding the foregoing provisions of this Section 5.3, if the Executive breaches the Executive’s obligations
under Section 6 at any time, from and after the date of such breach and not in any way in limitation of any right or remedy otherwise available to the Company, the Executive shall no longer be entitled to, and the Company shall no longer
be obligated to pay, any remaining unpaid portion of the Severance Benefit or CIC Severance Benefit, as applicable; provided, however, that, if the Executive provides the release contemplated by Section 5.4, in no event
shall the Executive be entitled to a Severance Benefit or CIC Severance Benefit, as applicable, payment of less than $5,000, which amount the parties agree is good and adequate consideration, in and of itself, for the Executive’s release
contemplated by Section 5.4. 
 (e) The foregoing provisions of this Section 5.3 shall not affect:
(a) the Executive’s receipt of benefits otherwise due terminated employees under group insurance coverage consistent with the terms of the applicable Company welfare benefit plan; (b) the Executive’s rights under COBRA to
continue participation in medical, dental, hospitalization and life insurance coverage; or (c) the Executive’s receipt of benefits otherwise due in accordance with the terms of the Company’s 401(k) plan (if any). 

5.4 Release; Exclusive Remedy. 
 (a) This Section 5.4 shall apply notwithstanding anything else contained in this Agreement or any stock option or other equity-based award agreement to the contrary. As a condition precedent
to any Company obligation to the Executive pursuant to Section 5.3(b) or Section 5.3(c), the Executive shall, upon or promptly following the Executive’s last day of employment with the Company (and in all events within
twenty-one (21) days after the Executive’s last day of employment with the Company), provide the Company with a valid, executed general release agreement in a form acceptable to the Company, and such release agreement shall have not been
revoked by the Executive pursuant to any revocation rights afforded by applicable law. 
 (b) The Executive agrees that the
payments and benefits contemplated by Section 5.3 shall constitute the exclusive and sole remedy for any termination of the Executive’s employment and the Executive covenants not to assert or pursue any other remedies, at law or in

  
 - 6 -

 equity, with respect to any termination of employment. The Company and the Executive acknowledge and agree
that there is no duty of the Executive to mitigate damages under this Agreement. All amounts paid to the Executive pursuant to Section 5.3 shall be paid without regard to whether the Executive has taken or takes actions to mitigate
damages. The Executive shall resign, on the Severance Date, as an officer and director of the Company and any Affiliate of the Company, and as a fiduciary of any benefit plan of the Company or any Affiliate of the Company, and to promptly execute
and provide to the Company any further documentation, as requested by the Company, to confirm such resignation. 
 5.5
Certain Defined Terms. 
 (a) As used herein, “Accrued Obligations” means: 

(i) any Base Salary that had accrued, but had not been paid (including accrued and unpaid vacation time), on or before the Severance
Date; and 
 (ii) any Incentive Bonus payable pursuant to Section 3.2 with respect to any fiscal year in the Period
of Employment preceding the fiscal year in which the Severance Date occurs, if the Company had paid bonuses generally with respect to such fiscal year on or prior to the Severance Date but had not previously paid any Incentive Bonus due to the
Executive with respect to such fiscal year; and 
 (iii) any reimbursement due to the Executive pursuant to
Section 4.2 for expenses reasonably incurred by the Executive on or before the Severance Date and documented and pre-approved, to the extent applicable, in accordance with the Company’s expense reimbursement policies in effect at
the applicable time. 
 (b) As used herein, “Affiliate” of the Company means a Person that directly or
indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company. As used in this definition, the term “control,” including the correlative terms “controlling,”
“controlled by” and “under common control with,” means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or
other ownership interest, by contract or otherwise) of a Person. 
 (c) As used herein, “Cause” shall mean, as
determined by the Board (excluding the Executive, if the Executive is then a member of the Board) based on the information then known to the Board, that one or more of the following has occurred: 

(i) the Executive has committed a felony (under the laws of the United States or any relevant state, or a similar crime or offense under
the applicable laws of any relevant foreign jurisdiction); 
 (ii) the Executive has engaged in acts of fraud, dishonesty or
other acts of willful misconduct in the course of the Executive’s duties hereunder; 
 (iii) the Executive fails to
perform or uphold the Executive’s duties under this Agreement and/or fails to comply with reasonable directives of the Board or the CEO; or 

  
 - 7 -

 (iv) any breach by the Executive of any provision of Section 6, or of the
Confidentiality Agreement (as such term is defined in Section 6.1(c)) or any breach by the Executive of any other contract the Executive is a party to with the Company or any of its Affiliates. 

(d) As used herein, “Change in Control” shall mean the consummation of a reorganization, merger, statutory share
exchange or consolidation or similar corporate transaction involving the Company or any corporation or other entity a majority of whose outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company (a
“Subsidiary”), a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its Subsidiaries (each, a “Business
Combination”), in each case that results in the holders of the Company’s outstanding voting power immediately prior to the Business Combination ceasing to beneficially own, directly or indirectly, more than 50% of the combined voting
power of the then-outstanding voting securities entitled to vote generally in the election of directors of the entity resulting from such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the
Company or all or substantially all of the Company’s assets directly or through one or more subsidiaries). 
 (e) As used
herein, “Disability” shall mean the Executive is determined to be eligible for disability benefits under the long-term disability plan or policy of the Company then applicable to the Executive. 

(f) As used herein, “Good Reason” shall mean the occurrence of any of the following events without Executive’s
prior written consent: 
 (i) a material diminution in Executive’s base compensation; 

(ii) a material diminution in Executive’s authority, duties or responsibilities; 

(iii) a material change in geographic location at which Executive performs services; or 

(iv) any material breach by the Company of this Agreement; 
 provided, however, that no such event or condition shall constitute Good Reason unless (x) Executive gives the Company a written notice of termination for Good Reason not more than
90 days after the initial existence of the condition, (y) the grounds for termination (if susceptible to correction) are not corrected by the Company within 30 days of its receipt of such notice and (z) Executive’s
termination of employment occurs within one year following the Company’s receipt of such notice. 
 (g) As used herein, the
term “Person” shall be construed broadly and shall include, without limitation, an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an
unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. 

  
 - 8 -

 (f) As used herein, a “Separation from Service” occurs when the Executive
dies, retires, or otherwise has a termination of employment with the Company that constitutes a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h)(1), without regard to the optional alternative
definitions available thereunder. 
 5.6. Notice of Termination. Any termination of the Executive’s
employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party. This notice of termination must be delivered in accordance with Section 18 and must indicate the
specific provision(s) of this Agreement relied upon in effecting the termination. 
 5.7 Section 280G.

 (a) Notwithstanding anything contained in this Agreement to the contrary, to the extent that any payment, benefit or
distribution of any type to or for the benefit of the Executive by the Company or any of the Company’s affiliates, whether paid or payable, provided or to be provided, or distributed or distributable pursuant to the terms of this Agreement or
otherwise (including, without limitation, any accelerated vesting of stock options or other equity-based awards) (collectively, the “Total Payments”) would be subject to the excise tax imposed under Section 4999 of the Internal
Revenue Code of 1986, as amended (the “Code”), then the Total Payments shall be reduced (but not below zero) so that the maximum amount of the Total Payments (after reduction) shall be One Dollar ($1.00), less than the amount which
would cause the Total Payments to be subject to the excise tax imposed by Section 4999 of the Code; provided, however, that the reduction shall occur only if the reduced Total Payments (after taking into account further reductions
for applicable federal, state, and local income, social security and other taxes) would be greater than the unreduced Total Payments minus (i) the excise tax imposed under Code Section 4999 with respect to the Total Payment and
(ii) all applicable federal, state, and local income, social security and other taxes with respect to the Total Payments. To the extent that the Total Payments are required to be reduced pursuant to the preceding sentence, then, unless the
Executive shall have given prior written notice to the Company to effectuate a reduction in the Total Payments if such a reduction is required, any such notice consistent with the requirements of Section 409A of the Code to avoid the imputation
of any tax, penalty or interest thereunder, the Company shall reduce or eliminate the Total Payments by first reducing or eliminating any cash severance benefits (with the payments to be made furthest in the future being reduced first), then by
reducing or eliminating any accelerated vesting of stock options or similar awards, then by reducing or eliminating any accelerated vesting of restricted stock or similar awards, then by reducing or eliminating any other remaining Total Payments.
The preceding provisions of this Section 5.7(a) shall take precedence over the provisions of any other plan, arrangement or agreement governing the Executive’s rights and entitlements to any benefits or compensation. 

(b) Any determination that Total Payments to the Executive must be reduced or eliminated in accordance with Section 5.7(a)
and the assumptions to be utilized in arriving at such determination, shall be made by the Board in the exercise of the Board’s discretion based 

  
 - 9 -

 
upon the advice of such professional advisors it may deem appropriate in the circumstances. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the
initial determination by the Board hereunder, it is possible that Total Payments to the Executive which will not have been made by the Company should have been made (“Underpayment”). If an Underpayment has occurred, the amount of
any such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive. In the event that any Total Payment made to the Executive shall be determined to otherwise result in the imposition of any tax under
Section 4999 of the Code, then the Executive shall promptly repay to the Company the amount of any such overpayment together with interest on such amount (at the same rate as is applied to determine the present value of payments under
Section 280G of the Code or any successor thereto), from the date the reimbursable payment was received by the Executive to the date the same is repaid to the Company. 
 6. Protective Covenants. 
 6.1 Confidential Information;
Inventions. 
 (a) The Executive shall not disclose or use at any time, either during the Period of Employment or
thereafter, any Confidential Information (as defined below) of which the Executive is or becomes aware, whether or not such information is developed by the Executive, except to the extent that such disclosure or use is directly related to and
required by the Executive’s performance in good faith of the Executive’s duties for the Company. The Executive shall take all appropriate steps to safeguard Confidential Information in the Executive’s possession and to protect the
Company against disclosure, misuse, espionage, loss and theft. The Executive shall deliver to the Company at the termination of the Period of Employment, or at any time the Company may request, all memoranda, notes, plans, records, reports, computer
tapes and software and other documents and data (and copies thereof) relating to the Confidential Information or the Work Product (as hereinafter defined) of the business of the Company or any of its Affiliates which the Executive may then possess
or have under the Executive’s control. Notwithstanding the foregoing, the Executive may truthfully respond to a lawful and valid subpoena or other legal process, but shall give the Company the earliest possible written notice thereof, shall, as
much in advance of the return date as possible, make available to the Company and its counsel the documents and other information sought, and shall assist the Company and such counsel in resisting or otherwise responding to such process. 

(b) Definitions. 
 (i) As used in this Agreement, the term “Confidential Information” means information that is not generally known to the public and that is used, developed or obtained by the Company in
connection with its business, including, but not limited to, information, observations and data obtained by the Executive while employed by the Company or any predecessors thereof (including those obtained prior to the Effective Date) concerning
(1) the business or affairs of the Company (or such predecessors), (2) products or services, (3) fees, costs and pricing structures, (4) designs, (5) analyses, (6) drawings, photographs and reports, (7) computer
software, including operating systems, applications and program listings, (8) flow charts, manuals and documentation, (9) data bases, (10) accounting and business methods, (11) inventions, devices, new developments, methods and
processes, whether 

  
 - 10 -

 patentable or unpatentable and whether or not reduced to practice, (12) customers and clients and
customer or client lists, (13) other copyrightable works, (14) all production methods, processes, technology and trade secrets, and (15) all similar and related information in whatever form. Confidential Information shall not include
any information that has been published (other than a disclosure by the Executive in breach of this Agreement) in a form generally available to the public prior to the date the Executive proposes to disclose or use such information. Confidential
Information shall not be deemed to have been published merely because individual portions of the information have been separately published, but only if all material features comprising such information have been published in combination.

 (ii) As used in this Agreement, the term “Work Product” means all inventions, innovations, improvements,
technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, trade names, logos and all similar or related information (whether patentable or unpatentable, copyrightable,
registerable as a trademark, reduced to writing, or otherwise) which relates to the Company’s or any of its Affiliates’ actual or anticipated business, research and development or existing or future products or services and which are
conceived, developed or made by the Executive (whether or not during usual business hours, whether or not by the use of the facilities of the Company or any of its Affiliates, and whether or not alone or in conjunction with any other person) while
employed by the Company (including those conceived, developed or made prior to the Effective Date) together with all patent applications, letters patent, trademark, trade name and service mark applications or registrations, copyrights and reissues
thereof that may be granted for or upon any of the foregoing. All Work Product that the Executive may have discovered, invented or originated during the Executive’s employment by the Company or any of its Affiliates prior to the Effective Date,
that the Executive may discover, invent or originate during the Period of Employment or at any time in the period of twelve (12) months after the Severance Date, shall be the exclusive property of the Company and its Affiliates, as applicable,
and the Executive hereby assigns all of the Executive’s right, title and interest in and to such Work Product to the Company or its applicable Affiliate, including all intellectual property rights therein. The Executive shall promptly disclose
all Work Product to the Company, shall execute at the request of the Company any assignments or other documents the Company may deem necessary to protect or perfect the Company’s (or any of its Affiliates’, as applicable) rights therein,
and shall assist the Company in obtaining, defending and enforcing the Company’s (or any of its Affiliates’, as applicable) rights therein. The Executive hereby appoints the Company as the Executive’s attorney-in-fact to execute on
the Executive’s behalf any assignments or other documents deemed necessary or advisable by the Company to protect or perfect the Company, the Company’s (and any of its Affiliates’, as applicable) rights to any Work Product.

 (c) The Executive shall promptly execute the form of Confidentiality, Proprietary Information and Inventions Agreement (the
“Confidentiality Agreement”) generally applicable to employees of the Company at the time that such agreement is finalized and delivered to the Executive. 
 6.2 Restriction on Competition. The Executive agrees that if the Executive were to become employed by (or contract to become employed by), or substantially involved in, the business of a
competitor of the Company or any of its Affiliates during the twelve (12) months following the Severance Date, it would be very difficult for the Executive not to rely on or use 

  
 - 11 -

 
the Company’s and its Affiliates’ trade secrets and confidential information. Thus, to avoid the inevitable disclosure of the Company’s and its Affiliates’ trade secrets and
confidential information, and to protect such trade secrets and confidential information and the Company’s and its Affiliates’ relationships and goodwill with customers, during the Period of Employment and for a period of twelve
(12) months after the Severance Date, the Executive shall not directly or indirectly through any other Person engage in, enter the employ of (or contract to enter the employ of), render any services to, have any ownership interest in, nor
participate in the financing, operation, management or control of, any Competing Business. For purposes of this Agreement, the phrase “directly or indirectly through any other Person engage in” shall include, without limitation, any direct
or indirect ownership or profit participation interest in such enterprise, whether as an owner, stockholder, member, partner, joint venturer or otherwise, and shall include any direct or indirect participation in such enterprise as an employee,
consultant, director, officer, licensor of technology or otherwise. For purposes of this Agreement, “Competing Business” means any Person anywhere in the world that at any time during the Period of Employment is engaged in (or has
plans to engage in), or at any time during the six (6) month period following the Severance Date is engaged in (or has plans to engage in) any business engaged in the late stage development, registration, or commercialization of an antibiotic
with activity against methicillin resistant staphylococcus. Nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2% )of the outstanding stock of any class of a corporation which is publicly traded, so
long as the Executive has no active participation in the business of such corporation. 
 6.3 Soliciting
Customers. During the Period of Employment and for a period of twelve (12) months after the Severance Date, the Executive shall not, directly or indirectly through any other Person, influence or attempt to influence customers, vendors,
suppliers, licensors, lessors, joint venturers, associates, consultants, agents, or partners of the Company or any of its Affiliates to divert their business away from the Company or such Affiliate, and the Executive shall not otherwise interfere
with, disrupt or attempt to disrupt the business relationships, contractual or otherwise, between the Company or any of its Affiliates, on the one hand, and any of its or their customers, suppliers, vendors, lessors, licensors, joint venturers,
associates, officers, employees, consultants, managers, partners, members or investors, on the other hand. 
 6.4
Soliciting Employees and Consultants. During the Period of Employment and for a period of twelve (12) months after the Severance Date, the Executive shall not directly or indirectly through any other Person (a) induce or attempt
to induce any employee or independent contractor of the Company or any of its Affiliates to leave the employ or service, as applicable, of the Company or such Affiliate, or in any way interfere with the relationship between the Company or any such
Affiliate, on the one hand, and any employee or independent contractor thereof, on the other hand, or (b) hire any person who was an employee of the Company or any of its Affiliates until six (6) months after such individual’s
employment relationship with the Company or such Affiliate has been terminated. 
 6.5 Understanding of Covenants.
The Executive acknowledges that, in the course of the Executive’s employment with the Company and/or its Affiliates and their predecessors, the Executive has become familiar, or will become familiar, with the Company’s and its
Affiliates’ and their predecessors’ trade secrets and with other confidential and proprietary 

  
 - 12 -

 
information concerning the Company, its Affiliates and their respective predecessors and that the Executive’s services have been and will be of special, unique and extraordinary value to the
Company and its Affiliates. The Executive agrees that the foregoing covenants set forth in this Section 6 (together, the “Restrictive Covenants”) are reasonable and necessary to protect the Company’s and its
Affiliates’ trade secrets and other confidential and proprietary information, good will, stable workforce, and customer relations. 
 Without limiting the generality of the Executive’s agreement in the preceding paragraph, the Executive (a) represents that the Executive is familiar with and has carefully considered the
Restrictive Covenants, (b) represents that the Executive is fully aware of the Executive’s obligations hereunder, (c) agrees to the reasonableness of the length of time, scope and geographic coverage, as applicable, of the Restrictive
Covenants, (d) agrees that the Company and its Affiliates currently conduct business throughout the world, and (e) agrees that the Restrictive Covenants shall continue in effect for the applicable periods set forth above in this
Section 6 regardless of whether the Executive is then entitled to receive severance pay or benefits from the Company. The Executive understands and agrees that the Restrictive Covenants may limit the Executive’s ability to earn a
livelihood in a business similar to the business of the Company and any of its Affiliates, but the Executive nevertheless believes that the Executive has received and will receive sufficient consideration and other benefits as an employee of the
Company and as otherwise provided hereunder or as described in the recitals hereto to clearly justify such restrictions which, in any event (given the Executive’s education, skills and ability), the Executive does not believe would prevent the
Executive from otherwise earning a living. The Executive agrees that the Restrictive Covenants do not confer a benefit upon the Company disproportionate to the detriment of the Executive. 

6.6 Enforcement. The Executive agrees that the Executive’s services are unique and that the Executive has access to
Confidential Information and Work Product. Accordingly, without limiting the generality of Section 17, the Executive agrees that a breach by the Executive of any of the covenants in this Section 6 or of the Confidentiality
Agreement would cause immediate and irreparable harm to the Company that would be difficult or impossible to measure, and that damages to the Company for any such injury would therefore be an inadequate remedy for any such breach. Therefore, the
Executive agrees that in the event of any breach or threatened breach of any provision of this Section 6 or of the Confidentiality Agreement, the Company shall be entitled, in addition to and without limitation upon all other remedies
the Company may have under this Agreement, at law or otherwise, to obtain specific performance, injunctive relief and/or other appropriate relief (without posting any bond or deposit) in order to enforce or prevent any violations of the provisions
of this Section 6 or of the Confidentiality Agreement, or require the Executive to account for and pay over to the Company all compensation, profits, moneys, accruals, increments or other benefits derived from or received as a result of
any transactions constituting a breach of this Section 6 or of the Confidentiality Agreement, if and when final judgment of a court of competent jurisdiction is so entered against the Executive. The Executive further agrees that the
applicable period of time any Restrictive Covenant is in effect following the Severance Date, as determined pursuant to the foregoing provisions of this Section 6, such period of time shall be extended by the same amount of time that the
Executive is in breach of any Restrictive Covenant. 

  
 - 13 -

 7. Withholding Taxes. Notwithstanding anything else herein to the contrary, the Company may
withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be required to be withheld pursuant to
any applicable law or regulation. 
 8. Successors and Assigns. 

8.1 Non-Assignable. This Agreement is personal to the Executive and without the prior written consent of the Company shall
not be assignable by the Executive. 
 8.2 Successors. This Agreement shall inure to the benefit of and be binding
upon the Company and its successors and assigns. Without limiting the generality of the preceding sentence, the Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in
this Agreement, the “Company” shall mean the Company as hereinbefore defined and any successor or assignee, as applicable, which assumes and agrees to perform this Agreement by operation of law or otherwise. 

9. Number and Gender; Examples. Where the context requires, the singular shall include the plural, the plural shall include the singular,
and any gender shall include all other genders. Where specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the
general statement to which it relates. 
 10. Section Headings. The section headings of, and titles of paragraphs and
subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction or interpretation thereof. 

11. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING
EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEW YORK TO BE APPLIED. IN FURTHERANCE OF THE FOREGOING,
THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL CONTROL THE INTERPRETATION AND CONSTRUCTION OF THIS AGREEMENT, EVEN IF UNDER SUCH JURISDICTION’S CHOICE OF LAW OR CONFLICT OF LAW ANALYSIS, THE SUBSTANTIVE LAW OF SOME OTHER JURISDICTION WOULD
ORDINARILY APPLY. 
 12. Severability. It is the desire and intent of the parties hereto that the provisions of this Agreement be
enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Agreement shall be adjudicated by a court of competent
jurisdiction to be invalid, prohibited or unenforceable under any present or future law, and if the rights and 

  
 - 14 -

 
obligations of any party under this Agreement will not be materially and adversely affected thereby, such provision, as to such jurisdiction, shall be ineffective, without invalidating the
remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction, and to this end the provisions of this Agreement are declared to be severable; furthermore, in lieu of such invalid or
unenforceable provision there will be added automatically as a part of this Agreement, a legal, valid and enforceable provision as similar in terms to such invalid or unenforceable provision as may be possible. Notwithstanding the foregoing, if such
provision could be more narrowly drawn (as to geographic scope, period of duration or otherwise) so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating
the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction. 
 13.
Entire Agreement. This Agreement embodies the entire agreement of the parties hereto respecting the matters within its scope. This Agreement supersedes all prior and contemporaneous agreements of the parties hereto that directly or
indirectly bears upon the subject matter hereof. Any prior negotiations, correspondence, agreements, proposals or understandings relating to the subject matter hereof shall be deemed to have been merged into this Agreement, and to the extent
inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be deemed to be of no force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral or written,
with respect to the subject matter hereof, except as expressly set forth herein. 
 14. Modifications. This Agreement may not be
amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring to this Agreement, which agreement is executed by both of the parties hereto. 

15. Waiver. Neither the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement
shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right,
remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party
asserted to have granted such waiver. 
 16. Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT
TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 17. Remedies. Each of
the parties to this Agreement and any such person or entity granted rights hereunder whether or not such person or entity is a signatory hereto shall be entitled to enforce its rights under this Agreement specifically to recover damages and costs
for any breach of any provision of this Agreement and to exercise all other rights existing in its favor. The parties hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement
and that each party may in its sole discretion apply to any court of law or equity of competent jurisdiction for specific performance, injunctive 

  
 - 15 -

 
relief and/or other appropriate equitable relief (without posting any bond or deposit) in order to enforce or prevent any violations of the provisions of this Agreement. Each party hereto shall
be responsible for paying its own attorneys’ fees, costs and other expenses pertaining to any such legal proceeding and enforcement regardless of whether an award or finding or any judgment or verdict thereon is entered against either party.

 18. Notices. Any notice provided for in this Agreement must be in writing and must be either personally delivered, transmitted
via telecopier, mailed by first class mail (postage prepaid and return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the recipient at the address below indicated or at such other address or to the attention
of such other person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder and received when delivered personally, when received if transmitted via telecopier, five
days after deposit in the U.S. mail and one day after deposit with a reputable overnight courier service. 
 if to the Company:

 Durata Therapeutics, Inc. 
 89 Headquarters Plaza North 
 14th Floor 

Morristown, NJ 87690 
 Attn: Mr. Paul Edick 
 With a copy to: 

WilmerHale 

399 Park Avenue 

New York, NY 10022 
 Attn: Andrew Nagel, Esq. 
 if to the Executive: 

19. Section 409A. 
 19.1 Six-Month Delay for Specified Employees. If the Executive is a “specified employee” within the meaning of Treasury Regulation Section 1.409A-1(i) as of the date of
the Executive’s Separation from Service, the Executive shall not be entitled to any payment or benefit pursuant to Section 5.3(b) or, if applicable, Section 5.3(c) until the earlier of (i) the date which is six
(6) months after the Executive’s Separation from Service for any reason other than death, or (ii) the date of the Executive’s death. The provisions of this paragraph shall only apply if, and to the extent, required to avoid the
imputation of any tax, penalty or interest pursuant to Section 409A of the Code. Any amounts otherwise payable to the Executive upon or in the six (6) month period following the Executive’s Separation from Service that are not so paid
by reason of this Section 19.1 shall be paid (without interest) as soon as practicable (and in all 

  
 - 16 -

 
events within thirty (30) days) after the date that is six (6) months after the Executive’s Separation from Service (or, if earlier, as soon as practicable, and in all events
within thirty (30) days, after the date of the Executive’s death). 
 19.2 Reimbursements. To the extent
that any benefits pursuant to Section 4.2 are taxable to the Executive, any reimbursement payment due to the Executive pursuant to such provision shall be paid to the Executive on or before the last day of the Executive’s taxable
year following the taxable year in which the related expense was incurred. The benefits pursuant to Section 4.2 are not subject to liquidation or exchange for another benefit and the amount of such benefits that the Executive receives in
one taxable year shall not affect the amount of such benefits that the Executive receives in any other taxable year. 
 19.3
Construction. It is intended that any amounts payable under this Agreement and the Company’s and the Executive’s exercise of authority or discretion hereunder shall comply with and avoid the imputation of any tax, penalty or
interest under Section 409A of the Code. This Agreement shall be construed and interpreted consistent with that intent. 
 20.
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same
instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed
counterparts may be used in lieu of the originals for any purpose. 
 21. Legal Counsel; Mutual Drafting. Each party recognizes
that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with legal counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in
any construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such language. The Executive agrees and acknowledges that he has read and understands this Agreement,
is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so. 
 [The remainder of this page has intentionally been left blank.] 

  
 - 17 -

 IN WITNESS WHEREOF, the Company and the Executive have executed this
Agreement as of the Effective Date. 
  

			
	 “COMPANY”

 
 Durata Therapeutics, Inc.,

a Delaware corporation

		
	 By:
	 	 /S/ PAUL R. EDICK

	 Name:
	 	 Paul R. Edick

	 Title:
	 	 C.E.O

	
	 “EXECUTIVE”

	
	 /S/ JOHN SHANNON

	 John Shannon

  
 - 18 -Supply Agreement

 Exhibit 10.17 

 

					
		 	
Confidential Materials omitted and filed separately with
 the Securities and Exchange Commission. Asterisks denote omissions.
	 	

 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (this “Agreement”) entered into this 12 day of June 2012 (the “Effective
Date”) by and between Gnosis Bioresearch srl., a subsidiary fully owned company by GNOSIS SPA organized under the laws of Italy whose head office is located at Via Pomarico, 75010 Pisticci Scalo (MT), Italy, which is registered in
the Commercial Register of Matera under No. 01023770777 (“Gnosis”), and Durata Therapeutics, Inc., a company organized under the laws of the State of Delaware with offices at 89 Headquarters Plaza North, 14th Floor, Morrison, NJ 07960 USA (“Durata”). 

 WITNESSETH 
 WHEREAS, Durata owns rights in the product Dalbavancin and Gnosis has previously manufactured Dalbavancin for Durata, according to the Drug Master File (DMF) submitted to Agenzia Italiana del Farmaco
(AIFA); 
 WHEREAS, Gnosis shall supply to Durata the active pharmaceutical ingredient (“API”) Dalbavancin which will
be manufactured and supplied in the form of injectable grade powder to Durata under the terms and conditions of this Agreement; 
 NOW
THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties have agreed as follows: 

ARTICLE 1—DEFINITIONS 
 The following terms when used herein with capital letters shall have the meanings set forth or referenced below: 
 “Affiliate” means, with respect to a Party, any corporation, partnership, joint venture and/or firm which controls, is controlled by or is under common control with such Party. As used in
this definition, “control” means: (a) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors; and (b) in
the case of non-corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the non-corporate entity or the power to elect more than fifty percent (50%) of the members of the
governing body of such non-corporate entity. 
 “Agreement” has the meaning set forth in the recitals. 

“AIFA” means Agenzia Italiana del Farmaco, the Italian Medicines Agency that is the national authority responsible for drugs regulation
in Italy, or any successor governmental agency. 
 “API” has the meaning set forth in the recitals. 

“Business Day” means any day, other than Saturday, Sunday or any statutory holiday in any of (a) Milan, Italy or
(b) New York, New York USA, on which financial institutions in each such jurisdiction are open for business.  

“Certificate of Analysis” means the completed documents for each batch analysis for Dalbavancin based on current testing specifications
in accordance with cGMP. 

  
 - 1 -

 “cGMP” means the current good manufacturing practices for the manufacture of pharmaceutical
products and any precursors thereto promulgated in guidelines and regulations of standard compilations applicable and in effect during the Term, in particular US CFR 21 210&211 and EU Commission Directive 91/356/EEC and the applicable
corresponding national laws implementing such EU Directive. 
 “Claims” has the meaning set forth in Section 14.2.

 “Confidential Information” means any confidential or proprietary information disclosed (a) hereunder in writing and
identified as being confidential or, if disclosed orally, visually or through some other media, is identified as confidential at the time of disclosure and (b) prior to the Effective Date by or on behalf of either Party or its Affiliates to the
other Party or its Affiliates related to Dalbavancin as disclosed under the Transition Services Agreement, except to the extent such information: 
 (i) is known to the recipient at the time of the disclosure, as evidenced by its written records or other competent evidence; 
 (ii) is disclosed to the recipient by a Third Party lawfully in possession of such information and not under an obligation of nondisclosure; 

(iii) is or becomes patented, published or otherwise part of the public domain through no fault of the recipient or its Affiliates; or

 (iv) is developed by or for the recipient without access to or use of the disclosing Party’s Confidential Information,
as evidenced by the recipient’s written records or other competent evidence. 
 “Drug Master File” means a document
submitted to the FDA, EMA or other Regulatory Authority used to provide confidential detailed information about facilities, manufacturing processes and materials used in manufacturing, processing, packaging and storing an active pharmaceutical
ingredient. 
 “Durata” has the meaning set forth in the recitals. 
 “Durata Intellectual Property” means all Intellectual Property owned or controlled by Durata as of the Effective Date or developed or acquired by Durata after the Effective Date. For
purposes of this definition, “controlled by” means possession of the right to grant a license or sublicense without violating (a) any law or governmental regulation applicable to such license or sublicense or (b) the terms
of any agreement or other arrangement with any Third Party. 
 “Durata Project IP” has the meaning set forth in
Section 2.3(b). 
 “Effective Date” has the meaning set forth in the recitals. 

“EMA” means the European Medicines Agency or any successor governmental agency. 

“EU” means the European Union, as its membership may be altered from time to time, and any successor thereto 

“Facility” means Gnosis’ Pisticci Plant, Italy facility, or such other manufacturing site agreed to by the Parties in writing.

 “FDA” means the United States Food and Drug Administration or any successor United States governmental agency. 

“Forecasted Quantities” has the meaning set forth in Section 4.2. 
 “Gnosis” has the meaning set forth in the recitals. 

  
 - 2 -

 “Gnosis Intellectual Property” means all Intellectual Property owned or controlled by
Gnosis as of the Effective Date or developed or acquired by Gnosis outside of this Agreement subsequent to the Effective Date. For purposes of this definition, “controlled by” means possession of the right to grant a license or
sublicense without violating (a) any law or governmental regulation applicable to such license or sublicense or (b) the terms of any agreement or other arrangement with any Third Party. 

“Gnosis Project IP” has the meaning set forth in Section 2.3(b). 
 “Governmental Authority” means any domestic or foreign entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including
any governmental authority, agency, department, board, commission, court, tribunal, judicial body or instrumentality of any union of nations, federation, nation, state, municipality, county, locality or other political subdivision thereof.

 “Indemnitee” has the meaning set forth in Section 14.6. 

“Initial Term” has the meaning set forth in Section 10.1. 
 “Intellectual Property” means all patents, copyrights, trade secrets, know-how and all other intellectual property rights, anywhere in the world, including all applications and
registrations with respect thereto, but excluding all trademarks, trade names, service marks, logos and other corporate identifiers. 

“Joint Project IP” has the meaning set forth in Section 2.3(b). 
 “Legal Requirements” means laws applicable to the manufacture of the Product in North America and the EU, including the U.S. Federal Food, Drug, and Cosmetic Act, as amended, and the
regulations promulgated thereunder; European Directive 2003/94/EC and 2001/83/EC, and any amendments thereto and related legislation (if and when applicable); all applicable cGMP; and all other corresponding laws, ordinances, rules and regulations.
The Parties may jointly agree to amend the definition of “Legal Requirements” to include the laws of additional countries or territories, such amendment only to take effect upon written amendment of this Agreement, signed by both Parties

 “Losses” has the meaning set forth in Section 14.2. 
 “Main Supplier and Manufacturer” means a supplier producing not less than the [**]% of Durata’s worldwide demand for the Product. 

“Manufacturing Process” means the method of preparation and controls for the Product that is the property of Durata. 

 “Minimum binding annual volumes” has the meaning set forth in Section 4.1. 

“NDA” means a New Drug Application, including all supplements and amendments thereto, for the approval of a product as a new drug by the
FDA. 
 “Party” means Gnosis or Durata. “Parties” means Gnosis and Durata. 

“Person” means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or
other business entity, or any government or any agency or political subdivision thereof. 
 “Product” means the Dalbavancin API
in the form of injectable grade powder. 
 “Project Inventions” has the meaning set forth in Section 2.3(a).

  
 - 3 -

 “Purchase Order” has the meaning set forth in Section 4.3. 

“Quality Agreement” has the meaning set forth in Section 3.3(a). 
 “Regulatory Authority” means any federal, state or local or other regulatory agency, department, bureau or other governmental entity (including the FDA and the EMA), which is responsible
for issuing approvals, licenses, registrations or authorizations necessary for the manufacture, use, storage, import, transport, sale and use of the Product in any applicable regulatory jurisdiction. 

“Renewal Term” has the meaning set forth in Section 10.1. 
 “Safety Stock” has the meaning set forth in Section 4.5(d). 

“Specifications” has the meaning set forth in Section 3.1. 
 “Supply Prices” has the meaning set forth in Section 5.1. 

“Term” has the meaning set forth in Section 10.1. 
 “Third Party” means any natural or legal person, corporation, company, partnership or other entity other than Gnosis or Durata or Affiliates of Gnosis or Durata. 

“Transition Services Agreement” means the Reverse Transitional Services Agreement between Gnosis (as successor to Biosearch
Manufacturing S.r.l.) and Durata (as successor to Pfizer Italia S.r.l.), dated November 30, 2009, as amended. 

ARTICLE 2—LICENSE 
 2.1 Gnosis Proprietary Rights. Except as provided in Sections 2.3 and 2.4, Gnosis has granted no license, express or implied, to Durata to use Gnosis Intellectual Property. 

2.2 Durata’s Proprietary Rights. Except as set forth in Section 2.4 for the limited purposes of this Agreement.
Durata has granted no license, express or implied, to Gnosis to use Durata Intellectual Property. 
 2.3 Ownership of
Intellectual Property Developed under this Agreement. 
 (a) Durata shall be the sole owner of any technology, inventions,
know-how or other proprietary rights that are made, conceived or reduced to practice by Gnosis during the performance of this Agreement that pertain solely to the Product and its intermediates (“Project Inventions”) and Gnosis
hereby assigns all of its right, title and interest in Project Inventions, and all Intellectual Property therein, to Durata. Durata shall be entitled to apply for patent protection on such Project Inventions at Durata’s expense and risk. Gnosis
agrees to execute such assignments and other documents, to cause its employees, consultants and subcontractors to execute such assignments and other documents, and to take such other actions as may be reasonably requested by Durata from time to time
in order to effect to the ownership provisions of this Section 2.3(a). 
 (b) With respect to all other technology,
inventions, know-how or other proprietary rights that are made, conceived or reduced to practice during the performance of this Agreement, the following terms of ownership shall apply: Durata shall solely own all know-how and inventions made solely
by employees, consultants and/or subcontractors of Durata (the “Durata Project IP”) and Gnosis shall solely own know-how made and inventions made solely by employees, consultants and/or subcontractors of Gnosis (the “Gnosis
Project IP”). The Parties shall jointly own any know-how and inventions made jointly by employees, consultants and/or subcontractors of Durata and employees, consultants and/or subcontractors of Gnosis (the “Joint Project
IP”). Each Party shall 

  
 - 4 -

 
have the right to exploit and license the Joint Project IP without the prior consent of the other Party. Durata shall control the filing, prosecution, maintenance and enforcement of any patents
or patent applications covering the Joint Project IP and shall keep Gnosis regularly informed with respect to any such activities. The costs of any such filings, prosecution, maintenance and enforcement shall be shared equally by the Parties. Gnosis
shall, at Durata’s request, reasonably assist and cooperate in the filing, prosecution, maintenance and enforcement of any Joint Project IP. 
 2.4 License Grants. 
 (a) During the Term, Durata hereby grants to Gnosis a
fully paid, non-exclusive, non-transferable license under any and all Durata Intellectual Property, Project Inventions and Durata Project IP that is necessary for Gnosis to perform its obligations under this Agreement, for the sole and limited
purpose of Gnosis’ performing its obligations under this Agreement. 
 (b) Gnosis hereby grants to Durata an irrevocable,
fully paid, royalty-free, worldwide, non-exclusive license, with the right to grant and authorize sublicenses, under any and all Gnosis Intellectual Property or Gnosis Project IP that Gnosis incorporates into the Manufacturing Process or that is
otherwise necessary or useful for the practice of the Manufacturing Process, for the sole and limited purpose of manufacturing, or having manufactured Product. 
 ARTICLE 3—SUPPLY 
 3.1 Supply Generally. Subject
to the terms and conditions of this Agreement, Gnosis shall manufacture for and supply Durata with Product in conformity with (i) the specifications for Product set forth in Exhibit 3.1(i) (the “Specifications”),
(ii) the Quality Agreement, and (iii) cGMP, all applicable Legal Requirements and the applicable Drug Master File. 
 3.2 Delivery. Gnosis is the Main Supplier and shall deliver Product as directed by Durata, Ex-Works Pisticci Plant, Italy, to the sites designated by Durata in the purchase orders, in accordance
with (i) the International Chamber of Commerce’s Incoterms 2010 and (ii) the annual volumes and prices set forth in Exhibit 4.1. 
 3.3 Quality; Documentation. 
 (a) Promptly after Effective Date the Parties
shall enter into good faith discussions and use their respective good faith reasonable efforts to enter into a technical and quality agreement (the “Quality Agreement”) within [**] days from the Effective Date based on the
terms set out in Exhibit 3.3(a) pursuant to which, among other things, Gnosis will conduct all quality control and release testing for the Product. Such Quality Agreement shall be consistent with all Legal Requirements relating to the manufacture of
the Product. 
 (b) Product delivered by Gnosis to Durata shall be released by Gnosis’ quality control unit and shall be
accompanied by (i) the batch records check list for such Product; and (ii) a Certificate of Analysis signed by an authorized representative of Gnosis certifying that each batch of Product has been manufactured in accordance with the
Specifications. The full batch record will be sent upon specific request. 
 3.4 Specifications Generally. As of the
Effective Date, the Parties have reviewed and agreed on the Specifications, which are attached hereto as Exhibit 3.1(i). Subject to Section 8.1, Durata shall have the right to amend the Specifications from time to time;
provided, however, that Durata shall use commercially reasonable efforts to minimize the frequency of such changes and shall provide Gnosis with reasonable advance notice of any changes to the Specifications. Without in any way
limiting the foregoing, any modifications to the Specifications required by any Regulatory Authority with jurisdiction to require such modifications shall be made in accordance therewith. 

  
 - 5 -

 3.5 Non-Conforming Product. 

(a) Durata shall have the right but not the obligation to perform any tests to check the conformity to the Specifications of any Product
supplied hereunder. Durata shall notify Gnosis of any non-conformity within (i) [**] Business Days after receipt of the Product in the event of a defect discovered by Durata through the use of approved testing methods and procedures as referred
in the Specifications and in the Quality Agreement or (ii) [**] Business Days after Durata’s confirmation of the non-conforming status of the Product in the event of a defect (hidden or otherwise) which was not discoverable through the use
of such testing methods and procedures, and shall provide reasonable evidence thereof. 
 Durata shall have the right to notify
any non-conformity to Gnosis within a maximum period of [**] days from the Product delivery otherwise the Product shall be deemed unconditionally accepted by Durata. 
 (b) Gnosis will, within [**] Business Days of receipt of such a notification from Durata, notify Durata in writing whether Gnosis agrees to such non-conformity. 

(c) Gnosis will replace any non-conforming quantity of Product free of charge for Durata, including all shipping costs, within the
shortest feasible time period and in no event later than [**] days from (i) the receipt of the notification referred to in Section 3.5(a) or, (ii) if there is a disagreement between the parties as to the non-conformity, from
the date on which the independent expert laboratory referred to in Section 3.5(d) will have established the non-conformity of such Product and made the results of the tests showing such non-conformity known to the Parties. The
non-conforming quantity of Product will be returned to Gnosis, at Gnosis’ costs. 
 (d) Should Gnosis disagree on the
non-conformity of a batch of Product, the Parties will, within [**] Business Days of such Gnosis’ notification, appoint an independent expert laboratory (appointed by mutual agreement between the Parties, which agreement shall not be
unreasonably withheld, conditioned or delayed) who shall determine whether such Product is non-conforming. In the absence of manifest error, the independent expert laboratory’s decision shall be conclusive and binding on the Parties. The cost
of such analysis will be borne by the Party in error. 
 ARTICLE 4—VOLUMES, FORECASTS AND ORDERS 

4.1 Minimum annual binding purchase volumes of Product are set forth in Exhibit 4.1. In case such volumes are not achieved
in the relevant contract year of this Agreement, Gnosis shall be entitled to an increase of the agreed Supply Price set forth in Article 5. Such price adjustment shall be done in writing by mutual agreement and with formal amendment of the
Agreement.  
 4.2 Rolling Forecasts. Commencing [**] days after the acceptance by the FDA of the NDA submission
for the Product, Durata shall on or before the [**] Business Day of each [**] provide Gnosis with a [**] month non-binding forecast showing its estimated needs of Product, dispatched by month (the “Forecasted Quantities”).

 4.3 Purchase Orders. Durata shall issue binding purchase orders for any quantity of Product (“Purchase
Orders”) at least [**] days prior to the requested delivery dates. All Purchase Orders shall specify the quantity Product ordered, the destination to which the Product is to be delivered, the time and manner of delivery (including the
carrier to be used) and the delivery date. In the event that the quantity of Product ordered by Durata pursuant to this Section 4.3 for delivery in any one calendar month is more than [**] percent ([**]%) greater than the quantity of
Product reflected in the most recent Forecasted Quantities for such calendar month, Gnosis shall use commercially reasonable efforts, but shall not be obligated, to deliver during such calendar month the quantity of the Product ordered by Durata
beyond such threshold amount. 

  
 - 6 -

 4.4 Acceptance of Purchase Orders. Within [**] Business Days from receipt of any
Durata order, Gnosis will acknowledge receipt of such Purchase Order and confirm the delivery date for each shipment of Product. The only grounds upon which Gnosis may reject any Purchase Order shall be that such Purchase Order sets forth a
production and delivery schedule that is inconsistent with Section 4.3. If Gnosis does not reject a Purchase Order within [**] Business Days after receipt thereof, such Purchaser Order shall be deemed to be accepted by Gnosis.

 4.5 Shortage of Supply. In case Gnosis reasonably believes it will be unable to supply Product ordered under any
Purchase Order with respect to the ordered quantity or the requested delivery date, Gnosis shall inform Durata immediately in writing and the Parties will discuss in good faith an alternative delivery date and/or other appropriate measures.

 (a) In the event that Gnosis is unable to manufacture the Product in accordance with Durata’s Purchase Orders and such
inability is not: (i) caused by an event of force majeure; or (ii) primarily attributable to Durata’s acts or omissions or breach of its obligations under this Agreement, then Gnosis shall be solely responsible for undertaking
all commercially reasonable measures to minimize any possible shortage of Product to Durata as a result of its manufacturing issues. For the purposes of this Agreement, the term “force majeure” shall include only the following
contingencies: riot, war or hostilities between any nations, embargoes, orders or regulations of any government (national, state or local), acts of God, fire, accident, delays of carriers, lack of transportation facilities, inability to obtain raw
materials, curtailment of or failure in obtaining sufficient electrical power, or any other contingencies beyond the reasonable control of either Party, whether similar or dissimilar to any of the foregoing or strikes or differences with workmen.

 (b) In the event of a Supply Failure (as defined below), Durata shall have the right to purchase all of its requirements of
the Product from an alternative supplier until Gnosis demonstrates to Durata’s reasonable satisfaction that Gnosis has fully remedied such Supply Failure. “Supply Failure” shall mean Gnosis has failed to supply in a timely
manner at least (i) [**] percent ([**]%) of the Product ordered for delivery in any quarterly period with respect to a particular country, or (ii) [**] percent ([**]%) of the Product ordered for delivery in any [**] consecutive quarterly
periods with respect to a particular country. For purposes of this definition, any Product that is non-conforming Product at the time of delivery shall be considered not delivered. 

(c) At Durata’s request, Gnosis shall reasonably assist Durata in establishing and validating an alternative supplier of the
Product, including providing consulting assistance and conducting a technology transfer with respect to the Manufacturing Process for the Product. Durata shall reimburse Gnosis its reasonable out-of-pocket expenses and fees incurred in connection
with the technology transfer to the alternative supplier and for fees and expenses pre-approved by Durata that are incurred after technology transfer (such as assistance in implementation or scale-up of the manufacturing technology) based on
Gnosis’ then prevailing standard rates. 
 (d) In order to avoid a Supply Failure, at Durata’s written request, Gnosis
agrees to have manufactured at Durata’s expense, and stored on-site at the Facility, at least [**] Kilograms worth of safety stock (the “Safety Stock”) at all times for the remainder of the Term (or such other quantity as
specified by Durata). The initial Safety Stock quantity will be based upon the most recent Forecasted Quantities provided to Gnosis by Durata as of [**] days prior to the date that Durata notifies Gnosis in writing that the first commercial sale of
the Product by Durata has occurred. Thereafter, the Safety Stock quantity will be updated each [**] based upon the most recent Forecasted Quantities provided to Gnosis by Durata as of [**] days prior to such [**] date, as applicable. The inventory
of Safety Stock shall be managed on a first in first out basis. 

  
 - 7 -

 ARTICLE 5—SUPPLY PRICE 

5.1 Supply Price. The supply prices for Product shall be calculated in Euro per kg and shall subject to the price adjustment
schemes set forth in Sections 4.1, and 5.2 of this Agreement amount to the prices set forth in Exhibit 4.1 hereto (“Supply Prices”). 

5.2 Adjustments. Supply Prices may be adjusted on [**] basis on the anniversary of the Effective Date in case of, and in
accordance with: 
 (a) subject to clause (c), any significant change in the cost of components, utilities, raw materials used
in the Manufacturing Process to obtain Product. 
 (b) any significant change in the Consumer Price Index (ISTAT). Gnosis shall
have the right to increase the price of the Product [**] annually not to exceed the annual percentage increase for the most recent twelve (12) month period for which figures are available in the Consumer Price Index (ISTAT), assuming that Italy
continues to use the Euro as its currency or such other consumer price index as reasonably agreed by the Parties in the event Italy discontinues use of the Euro as its currency. 

(c) In the event Gnosis desires to adjust the Supply Price in accordance with clause (a), Gnosis and Durata shall meet within [**]
Business Days of written notice from Gnosis to Durata to review and agree on any and all price adjustments for the Products, if any. Prior to the meeting described above, Gnosis shall provide to Durata a cost matrix and a reasonably detailed summary
of its rationale for any price adjustment, together with any supporting documentation therefor. [**] price adjustments shall reflect increases or decreases in Gnosis’ cost of goods or manufacturing, taking into account any changes in
Gnosis’ aggregate costs for raw materials, Product components or utilities used in the manufacture of any Product. 
 (d)
Any such price adjustment under this Section shall be done in writing by mutual agreement and with formal amendment of the Agreement. Any price adjustments shall be effective from the date of signature by both of the Parties of the formal amendment
to this Agreement. 
 ARTICLE 6—INVOICING AND PAYMENT 

6.1 Issuance of Invoice. Gnosis shall invoice Durata upon each shipment of Product supplied to Durata. 

6.2 Payment. Durata shall pay all invoices issued by Gnosis within [**] days from the date of the invoice, assuming the invoice is
sent by electronic mail on the invoice date, by wire transfer to Gnosis’ designated bank account (as notified to Durata from time to time), subject to the fulfillment of Gnosis’ obligations pursuant to Article 3 hereto and the satisfactory
conformity test, if any, by Durata pursuant to Section 3.5 of this Agreement. Durata shall have the right to withhold payment of the portion of any invoice that is disputed in good faith under this Section 6.2 until such
dispute has been resolved. 
 6.3 Taxes. All sums payable hereunder shall be invoiced plus value added tax (VAT), if any
and if applicable. Each Party shall likewise be responsible for payment or reimbursement of other taxes federal, provincial or municipal taxes, levies, charges or fees imposed upon such Party with respect to the production, sale or delivery by
Gnosis to Durata of the Product in accordance with applicable laws, rules and regulations. 

  
 - 8 -

 ARTICLE 7—REPRESENTATIONS AND WARRANTIES 

7.1 Both Parties. Each Party represents and warrants as of the Effective Date that such Party: (a) is authorized to enter
into and perform this Agreement; (b) is aware of no legal, contractual or other restriction, limitation or condition that might affect adversely its ability to perform its obligations hereunder; and (c) is validly existing in each
jurisdiction in which it is incorporated and is authorized to do business under the laws of each jurisdiction in which it engages in business activities. Each Party further represents and warrants that as of the Effective Date it holds, and during
the Term will hold, all required governmental and regulatory approvals to fulfil its contractual obligations hereunder. 
 7.2
Gnosis Representations and Warranties. Gnosis represents and warrants to Durata that: 
 (a) all Product supplied to
Durata hereunder shall be (i) in conformity with the Specifications, (ii) manufactured in accordance with cGMP and with the applicable Drug Master File, (iii) not be adulterated or misbranded within the meaning of the United States
Federal Food, Drug, and Cosmetic Act, and (iv) delivered in accordance with the delivery date set forth in the applicable purchase orders confirmed by Gnosis; 
 (b) Gnosis shall use reasonable care in the manufacture of the Product under this Agreement in accordance with industry standards; 
 (c) the Facility and practices that shall be used in the performance of Gnosis’ obligations under this Agreement shall conform to the Legal Requirements; 

(d) in its performance of its obligations under this Agreement, Gnosis will not knowingly incorporate into the Manufacturing Process any
Intellectual Property of a Third Party for which it does not have a license that permits it to do so and/or to be able grant to Durata the licenses and other rights otherwise required to be granted to Durata hereunder; 

(e) neither Gnosis or any Gnosis Affiliate has never been, is not currently, and, during the term of this Agreement, will not become:
(i) an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) (“Debarred Individual”) from providing services in any capacity to a person that has an approved or pending drug product
application, or an employer, employee or partner of a Debarred Individual, or (ii) a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) (“Debarred
Entity”) from submitting or assisting in the submission of any abbreviated drug application, or an employee, partner, shareholder, member, subsidiary or affiliate of a Debarred Entity. Gnosis further warrants and represents that no Debarred
Individual or Debarred Entity has performed or rendered, or will perform or render, any services or assistance relating to activities taken pursuant to this Agreement. Gnosis further warrants and represents that Gnosis has no knowledge of any
circumstances which may affect the accuracy of the foregoing warranties and representations, including, but not limited to, FDA investigations of, or debarment proceedings against, Gnosis or any person or entity performing services or rendering
assistance relating to activities taken pursuant to this Agreement, and Gnosis will immediately notify Durata if Gnosis become aware of any such circumstances during the term of this Agreement. 

  
 - 9 -

 ARTICLE 8—CHANGE IN MANUFACTURING PROCESS AND FACILITY 

8.1 Changes to the Manufacturing Process or Facility. 
 (a) Prior Approval of Durata Required. Gnosis shall not make any change to the Manufacturing Process or the Facility (other than routine maintenance, reconditioning and/or replacement of equipment)
that would have an impact on the Product or require submissions to or approvals from any Regulatory Authority, except by prior written approval of Durata for such change, which approval shall not be unreasonably conditioned, withheld or delayed.

 (b) Changes Based on Applicable Legal Requirements. Gnosis shall make such changes to the Manufacturing Process or the
Facility as may be required pursuant to applicable law; provided that Gnosis shall have notified Durata in advance of any required change and shall have obtained the prior written approval of Durata for such change, which approval shall not be
unreasonably conditioned, withheld or delayed. Costs incurred by Gnosis in connection with such changes shall be reimbursed by Durata as follows: 
 (1) Changes Applicable to Durata’s Product. To the extent that changes to the Manufacturing Process and/or Facility are required pursuant to Legal Requirements applicable to the Product, costs
incurred for such changes shall be reimbursed by Durata on a Pro Rata Basis (as defined below) at cost. 
 (2) Changes in
Connection With Another Product. If changes to the Processing and/or Facility are required pursuant to Legal Requirements applicable to other activities in the Facility (even if such changes would not be required in the absence of the
Manufacturing Process of the Product at the Facility) the costs incurred for such changes shall not be reimbursed by Durata. 
 “Pro Rata
Basis” shall mean (A) the cost of the change required by Legal Requirements multiplied by (B) a percentage equal to the amount of manufacturing floor space at the Facility dedicated to the Product and affected by such change divided
by the total amount of manufacturing floor space at the Facility affected by such change. 
 (c) Changes Made at the Request
of Durata. From time to time, Durata may request that Gnosis make certain changes (other than those required by Legal Requirements) to the Manufacturing Process of the Product; provided, however, that (i) Durata shall seek to
minimize such changes, (ii) Durata shall enter into good faith negotiations with Gnosis regarding the assessment of the implications and costs arising from a change to the Manufacturing Process of the Product and (iii) after the Parties
have agreed upon the implications and costs related to a change to the Manufacturing Process of the Product, Gnosis shall implement such change. Costs incurred by Gnosis in connection with such changes shall be reimbursed by Durata at cost.

 (d) Improvements by Gnosis. If Gnosis identifies a potential improvement that would (i) require changes to the
Manufacturing Process or Facility, (ii) have an impact on the Product and/or (iii) require submissions to or approvals from any Regulatory Agency, then Gnosis shall notify Durata of such improvement and the Parties shall, in good faith,
discuss implementation of such improvement. Such improvement shall not be made unless the Parties reach agreement including, without limitation, agreement on allocation of cost, which agreement shall be at the sole discretion of the Parties.

  
 - 10 -

 ARTICLE 9—REGULATORY MATTERS 

9.1 Licenses and Permits. Gnosis shall be responsible for obtaining and maintaining during the Term, all licenses, permits,
registrations and regulatory approvals (federal, provincial and municipal) necessary to import raw materials and packaging components and to manufacture and supply the Product. 

9.2 Record Retention. Any books and records relating to the receipt, manufacture, storage, handling or testing of the Products,
raw materials and packaging components shall be maintained under this Agreement by a Party or its Affiliates or sublicensees in accordance with Legal Requirements. Without limiting the foregoing, Gnosis shall maintain a completed manufacturing
record, packaging record and analytical record, and shall retain samples, for each batch of Product manufactured for Durata and such other records as specified in the Quality Agreement for a period of time specified in the Quality Agreement. Gnosis
shall retain all such records at the Facility and provide copies or allow Durata access to such records as well as Gnosis’ internal operating procedures and specifications during normal business hours (subject to [**] Business Days prior
notice), provided allowing Durata access will not disrupt the operations of the business. 
 9.3 Regulatory Matters. At
all times during the Term, Gnosis shall maintain the Facility, equipment and processes (including, without limitation, the Manufacturing Process) used in producing the Products and in performing Gnosis’ other obligations under this Agreement
(a) in compliance in all material respects with employment and labor law requirements and electrical, fire and safety at work codes and regulations and (b) in compliance with all other applicable laws and regulations (including, without
limitation, cGMP requirements and guidelines issued by any applicable Regulatory Authorities, including, without limitation, national regulatory agencies or authorities). 
 9.4 Inspections by Durata. Upon reasonable notice to Gnosis, Durata shall have the right, alone or with consultants or designees, to (a) inspect the Facility and the equipment used or to be
used in processing Products; and (b) all documentation relating to compliance as described in Section 9.3, provided that any such inspection shall be conducted during normal business hours and in such a manner as to not unreasonably
disrupt business operations. 
 9.5 Inspections by Regulatory Authorities. Gnosis shall permit authorized officials of
the FDA, EMA or other Regulatory Authorities to inspect the Facility, including the equipment used in the manufacturing, filling, packaging, storage, testing, shipping or receiving of the Product. Each Party shall notify the other Party promptly
after such Party becomes aware that any such inspection is planned or imminent. To the extent permitted by Legal Requirements, Gnosis shall permit Durata to accompany the authorized officials of any such Regulatory Authority in its inspection.
Durata shall be provided copies of all reports and written communications submitted by any Regulatory Authority concerning such inspection and copies of any other written communication received by any Regulatory Authority relating to Product or the
Facility (if it relates to the manufacture or supply of Product) within [**] Business Days after receipt thereof by Gnosis. Gnosis will consult with Durata and consider Durata’s comments in good faith before responding to each such
communication. Gnosis shall provide Durata with its final responses within [**] days after submission thereof. Gnosis shall promptly remedy any deficiencies noted by the applicable Regulatory Authority and implement, at Gnosis’ expense, any
changes or improvements required if not solely related to Facility dedicated to the Product. 
 9.6 Technical Support.

 (a) Upon notification to Gnosis that Durata has received a complaint or inquiry regarding the safety, efficacy or quality of
a Product, Gnosis shall, within [**] days after such notification, supply Durata with a chemical analysis of a number of retained samples, maintained in accordance with the Quality Agreement, of the batch(es) of the Product in question. 

  
 - 11 -

 (b) Upon notification to Durata that Gnosis has received a complaint or inquiry regarding or
discovery by Durata of any issues relating to the safety, efficacy or quality of the Product, Durata shall, within a reasonable period, provide technical support as reasonably requested by Gnosis, which may include, but shall not limited to,
technical advice and chemical analysis of retained samples of the Product, maintained in accordance with the Quality Agreement. Technical support provided pursuant to this Section 9.6(b) shall not include any ordinary course material and
process assessments. 
 9.7 Regulatory Assistance. At Durata’s request, Gnosis shall review, consult with and advise
Durata in preparing submissions to and responding to questions from Regulatory Authorities regarding Durata’s filings for approval of the Product. 
 ARTICLE 10—TERM AND TERMINATION 
 10.1 Term. This
Agreement shall come into effect upon signature of this Agreement and shall continue, unless otherwise terminated pursuant to Section 10.2 or by mutual agreement between the Parties until the fifth (5) anniversary of the Effective
Date (the “Initial Term”). Thereafter, this Agreement shall automatically extend for additional terms of two (2) years (each, a “Renewal Term” and the Renewal Term(s) together with the Initial Term, the
“Term”) unless either Party provides the other Party written notice of its intent not to renew this Agreement at least twelve (12) months prior to the end of the then applicable. 

10.2 Termination for Material Breach. Either Party shall have the right to terminate this Agreement, with immediate effect, upon
any material breach of this Agreement by the other Party and the failure of the other Party to cure such breach within [**] days after written notice thereof. 
 10.3 Bankruptcy/Insolvency. Either Party may terminate this Agreement immediately by providing written notice to the other Party (i) if proceedings in voluntary or involuntary bankruptcy are
initiated by, on behalf of or against the other Party (and, in the case of any such involuntary proceeding, not dismissed within ninety (90) days), or (ii) if the other Party is adjudicated bankrupt, files a petition under insolvency Laws,
is dissolved or has a receiver appointed for substantially all of its property. 
 10.4 Return of Confidential
Information. Upon expiration or termination of this Agreement for any reason, the receiving Party shall immediately return to the disclosing Party all of the disclosing Party’s Confidential Information, in any form or medium disclosed by
the disclosing Party (or upon the disclosing Party’s instructions in writing, destroy the same and certify its destruction), provided, however, that (a) the receiving Party shall be allowed to retain one (1) copy of the
disclosing Party’s Confidential Information to ensure continuing compliance with Article 11; and (b) the licensee shall be allowed to retain the other’s Confidential Information as necessary to exploit the license granted to
the licensee pursuant to Section 2.3(b) or 2.3(c). 
 10.5 Survival. Expiration or early termination
of this Agreement shall not relieve either Party of any obligations that it may have incurred prior to expiration or early termination. The provisions of Articles 2, 11, 14 and 15 and Sections 3.5,10.4,10.5 shall survive
expiration or termination of this Agreement in accordance with their terms. 
 10.6 Accrued Rights. Termination,
relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination, relinquishment or expiration. Such termination, relinquishment
or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of this Agreement. 

  
 - 12 -

 ARTICLE 11—CONFIDENTIAL INFORMATION 

11.1 Nondisclosure. It is contemplated that in the course of the performance of this Agreement each Party may, from time to time,
disclose Confidential Information to the other. Gnosis agrees that, except as expressly provided herein, it shall not disclose Confidential Information received from Durata, and shall not use Confidential Information disclosed to it by Durata, for
any purpose other than to fulfill Gnosis’ obligations or exercise Gnosis’ rights hereunder. Durata agrees that, except as expressly provided herein, it shall not disclose Confidential Information received from Gnosis, and shall not use
Confidential Information disclosed to it by Gnosis, for any purpose other than to fulfill Durata’s obligations or exercise Durata’s rights hereunder. Each Party shall use reasonable and customary precautions to safeguard the other
Party’s Confidential Information, including ensuring that all employees, consultants and agents who are given access to such Confidential Information are informed of the confidential and proprietary nature of such Confidential Information and
have contractual or professional confidentiality and non-use obligations that are at least as restrictive as those contained in this Agreement. 
 11.2 Exceptions to Duty of Nondisclosure. 
 (a) Notwithstanding the above,
nothing contained in this Agreement shall preclude Durata from utilizing Gnosis’ Confidential Information in the following circumstances as may be necessary in prosecuting the patent and other Intellectual Property rights of Durata pursuant to
Article 2, obtaining governmental regulatory approvals, manufacturing Product pursuant to the terms and conditions of this Agreement, or complying with applicable laws or court orders (provided, however, that, where practical, Durata
uses reasonable efforts to seek confidential treatment of such information, except as required to file and prosecute such patent applications). 
 (b) The restrictions set forth in this Article 11 shall not apply to any of the disclosing Party’s Confidential Information that the receiving Party is required to disclose under applicable
laws or to defend or prosecute litigation, provided that the receiving Party: (i) provides the disclosing Party with prompt notice of such disclosure requirement if legally permitted, (ii) if legally permitted, affords the disclosing Party
an opportunity to oppose or limit, or secure confidential treatment for such required disclosure, and (iii) if the disclosing Party is unsuccessful in its efforts pursuant to subsection (ii), discloses only that portion of the Confidential
Information that the receiving Party is legally required to disclose. 
 (c) A Party may disclose Confidential Information of
the other Party to the extent such disclosure is reasonably necessary in the following instances: to its Affiliates, and to prospective and actual acquirers, licensees, sublicensees, employees, consultants, agents, accountants, lawyers, advisors and
investors, on a need to know basis, each of whom prior to disclosure must be bound by written or professional ethical obligations of confidentiality and non-use substantially equivalent in scope to those set forth in this Article 11 and that
are of reasonable duration in view of the circumstances of the disclosure; 
 (d) Each Party may disclose the terms of this
Agreement to the extent such Party is advised by counsel that such disclosure is required by applicable law (including by rules or regulations of the United States Securities and Exchange Commission (“SEC”), any other relevant
securities commission in any country, any securities exchange or NASDAQ); provided, that, (i) prior to such disclosure, to the extent permitted by applicable law or such rules or regulations, the disclosing Party promptly notifies the
other Party of such requirement and the disclosing Party furnishes only those terms of this Agreement that the disclosing Party is legally required to furnish, and (ii) specifically with respect to a filing of this Agreement pursuant to the
rules or regulations of the SEC, any other securities commission, any securities exchange or NASDAQ, the disclosing Party shall request, and use commercially reasonable efforts to obtain, confidential treatment of terms permitted to be redacted from
the forms of such agreements so filed under the applicable rules and regulations of the SEC, such securities commission, any securities exchange or NASDAQ, as applicable. Each Party shall, to the extent permitted under the relevant law or rules,
give the other Party a reasonable opportunity to review those portions of all filings with the SEC (or any other relevant securities commission in any country, any securities exchange or 

  
 - 13 -

 
NASDAQ) describing the terms of this Agreement (including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable and timely
comments by the non-filing Party relating to such filing, including the provisions of this Agreement for which confidential treatment should be sought; provided that each Party will ultimately retain control over what information that Party
discloses to their relevant securities commission or exchange. 
 11.3 Injunctive Relief. The Parties acknowledge that
either Party’s breach of this Article 11 may cause the other Party irreparable injury for which it would not have an adequate remedy at law. In the event of a breach, the non-breaching Party may be entitled to injunctive relief in
addition to any other remedies it may have at law or in equity. 
 11.4 Survival. The obligations of the Parties relating
to Confidential Information shall expire [**] years after the expiration or termination of this Agreement. 
 ARTICLE
12—APPLICABLE LAW—JURISDICTION 
 12.1 This Agreement shall be governed in all respects by the laws of the
State of New York, USA, including validity, interpretation and effect, without regard to the principles of conflicts of law that might otherwise be applicable. The parties hereto agree that the United Nations Convention on Contracts for the
International Sale of Goods shall not apply to determine any of the rights and obligations of the parties under this Agreement. 

12.2 Any dispute, controversy or claim arising out of or relating to this Agreement shall be resolved in accordance with the
provisions set forth in Exhibit 12.2.  
 ARTICLE 13—ASSIGNMENT 

13.1 Neither Party may assign this Agreement or any portion of this Agreement without the prior written consent of the other Party;
provided, however, (a) either Party shall have the right to transfer or assign this Agreement to any of its respective Affiliates, as the case may be, to the extent it provides the other Party with an unconditional and unqualified
guarantee of all the obligations of the assignee hereunder and (b) that Durata shall have the right to transfer or assign this Agreement to the Third-Party purchaser of the business which relates to the Product subject to the provisions of
Section 13.2. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve any Party of responsibility for the performance of any accrued obligation which such Party then has
hereunder. Any assignment made in violation of this Section shall be void. In any event, no change in the location of the manufacture of Product shall be made. 
 13.2 In the event that during the term of this Agreement, Durata sells its entire or a substantial part of its Dalbavancin business to a Third Party, Durata shall be obligated to transfer and assign this
Agreement to such Third Party in which case, and subject to the following provisions, this Agreement shall remain in full force and effect between Gnosis and such Third Party. All pricing provisions of Article 5 herein shall remain in full force and
effect. 
 ARTICLE 14—RECALL; INDEMNIFICATION; INSURANCE 

14.1 Investigation; Recall, Voluntary Withdrawal. In the event that any Governmental Authority in any country shall allege or
prove that a Product supplied hereunder does not comply with applicable laws, rules or regulations, Durata shall notify Gnosis immediately, and both Parties shall cooperate fully regarding the investigation and disposition of any such matter,
provided that Durata shall have the final decision making authority with respect to any such recall. If Durata is required to withdraw a Product, 

  
 - 14 -

 
then to the extent that such recall or withdrawal is due to any negligence, fraud, recklessness or wrongful intentional acts or omissions by or breach of any representation and warranty by
Gnosis, Gnosis shall reimburse Durata for the actual cost of manufacture (through final packaging) of the quantity of Product so recalled. Otherwise, Durata shall bear all costs and expenses associated with such recall or withdrawal. 

14.2 Indemnification by Gnosis. Subject to Section 14.3, Gnosis shall indemnify, defend and hold harmless Durata, its
Affiliates, its licensees and distributors, and their respective directors, officers, employees and agents, from and against any and all liabilities, damages, losses, costs or expenses whatsoever (including reasonable fees of attorneys and/or other
professionals) (“Losses”) arising out of or resulting from claims, demands or actions (“Claims”) by Third Parties based upon: 
 (a) any breach of Gnosis’s obligations, covenants, representations and warranties set forth in this Agreement or the Quality Agreement; 

(b) personal injury (including death) or property damage relating to or arising out of any manufacture of a Product by Gnosis or its
Affiliates due to Gnosis’s or its Affiliates failure to manufacture the Product in accordance with the applicable Specifications or any negligence, fraud, recklessness or wrongful intentional acts or omissions by, or strict liability of, Gnosis
or its Affiliates, and their respective directors, officers, employees and agents; and 
 (c) Gnosis’s or its
Affiliates’ negligence, fraud, recklessness or wrongful intentional acts or omissions in the manufacture of the Product. 

14.3 Indemnification by Durata. Subject to Section 14.2, Durata shall indemnify, defend and hold harmless Gnosis and
its Affiliates, and their respective directors, officers, employees and agents, from and against any and all Losses arising out of or resulting from Claims by Third Parties based upon: 

(a) any breach of Durata’s obligations, covenants, representations and warranties set forth in this Agreement or the applicable
Quality Agreement; 
 (b) personal injury (including death) or property damage relating to or arising out of any use,
distribution or sale of a Product by Durata, its Affiliates or its sublicensees due to any negligence, fraud, recklessness or wrongful intentional acts or omissions by, or strict liability of, Durata, its Affiliates or its sublicensees, and their
respective directors, officers, employees and agents; or 
 (c) Durata’s or its Affiliates’ negligence, fraud,
recklessness or wrongful intentional act or omission in the use of the Product. 
 14.4 Limitation on Indemnification.
Gnosis’ obligations under Section 14.2 and Durata’s obligations under Section 14.3 shall not apply to the extent that an indemnified Party’s Losses are attributable to any act constituting negligence, fraud,
recklessness, wrongful intentional act or omission on the part of such indemnified Party or any of its Affiliates or to the extent that such indemnified Party is otherwise responsible therefor. 

14.5 Consequential Damages. EXCEPT WITH RESPECT TO THE INDEMNIFICATION OBLIGATIONS SET FORTH IN THIS ARTICLE 14, UNDER NO
CIRCUMSTANCES WHATSOEVER (INCLUDING DUE TO NEGLIGENCE) SHALL EITHER PARTY BE LIABLE TO THE OTHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR (I) ANY (DIRECT OR INDIRECT) CONSEQUENTIAL LOSS OR DAMAGE, INCLUDING BUT
NOT LIMITED TO LOSS OF PROFITS, OF PRODUCTION, OF ANTICIPATED SAVINGS, PURE ECONOMIC LOSS, OF BUSINESS OR GOODWILL OR (II) ANY OTHER LIABILITY, DAMAGE, COSTS OR EXPENSE OF ANY KIND INCURRED BY THE OTHER PARTY OF AN INDIRECT OR CONSEQUENTIAL
NATURE, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 - 15 -

 14.6 Notice of Indemnification. In the event that any Person entitled to
indemnification (an “Indemnitee”) under Sections 14.2 or 14.3 is seeking such indemnification, such Indemnitee shall inform the indemnifying Party of the claim as soon as reasonably practicable after such Indemnitee
receives notice of such claim; provided that failure to give such notification shall not affect the indemnification provided under this Agreement, except to the extent the indemnifying Party shall actually have been prejudiced by such failure
in a material manner. Thereafter, the Indemnitee shall deliver to the indemnifying Party, promptly after the Indemnitee’s receipt thereof, copies of all notices and documents (including court papers) received by the Indemnitee relating to the
claim. The indemnifying Party shall have the right to assume the direction and control of the defense of the claim (including the sole right to settle it at the sole discretion of the indemnifying Party; provided that such settlement does not
impose any obligation on, or otherwise adversely affect, the Indemnitee) and shall cooperate as requested (at the expense of the indemnifying Party) in the defense of such claim. In any such proceeding the defense of which the indemnifying Party
shall have so assumed, the Indemnitee shall have the right to participate therein and retain its own counsel (without otherwise affecting the rights of the Parties under this Section 14.6) at its own expense unless (i) the
Indemnitee and the indemnifying Party shall have mutually agreed on the retention of counsel, (ii) the Indemnitee shall have reasonably concluded that there may be one or more legal defenses available to it which are different from or
additional to those available to the indemnifying Party, or (iii) the named Parties (including the impleaded Parties) include both the indemnifying Party and the Indemnitee, and representation of all Parties by the same counsel would be
inappropriate in the opinion of the indemnifying Party’s counsel due to actual or potential differing interests between them; in any such case, one firm of attorneys separate from the indemnifying Party’s counsel may be retained to
represent Indemnitee at the indemnifying Party’s expense. 
 14.7 Insurance. Gnosis shall, during the Term and for
two (2) years thereafter, maintain in force comprehensive general liability insurance on a claims-made basis, with endorsements for product liability with annual coverage limits of not less than [**] euros ([**]) per claim and [**] euros ([**])
annual aggregate. Gnosis shall name Durata as an additional insured on its policies with respect to Gnosis’s liabilities to Durata under this Agreement. The minimum level of insurance set forth herein shall not be construed to create a limit on
Gnosis’s liability hereunder. On the Effective Date and upon the request of Durata, Gnosis shall furnish to Durata a certificate of insurance evidencing such coverage as of such date. Each such certificate of insurance, as well as any
certificates evidencing new or modified coverages of Gnosis, shall include a provision whereby thirty (30) days written notice must be received by Durata prior to coverage modification or cancellation by either Gnosis or the insurer. In
addition, Gnosis shall promptly notify Durata of any cancellation or modification of such insurance coverage and of any new or modified coverage. In the case of a modification or cancellation of such coverage, Gnosis shall promptly provide Durata
with a new certificate of insurance evidencing that Gnosis coverage meets the requirements in the first sentence of this Section 14.7. 
 ARTICLE 15—GENERAL 
 15.1 Public Announcements. Gnosis
hereby covenants and agrees that neither Gnosis nor its Affiliates will make or issue any publicity, press releases or public announcements concerning this Agreement or the transactions contemplated by this Agreement without obtaining the prior
written approval for such public announcement. 
 15.2 Notices. All notices and other communications under this Agreement
shall be in writing in English and shall be either (i) sent by facsimile transmission to the number specified below, (ii) personally delivered against written discharge, or (iii) sent by registered mail to either Party at the address
specified below: 

  
 - 16 -

			
		
	Durata:	  	 Durata Therapeutics, Inc.
 89
Headquarters Plaza North
 14th Floor

Morristown, New Jersey 02960
 USA

Attention to: Mr. Corey Fishman
 Fax: +1 973
993 4869
 e-mail: cfishman@duratatherapeutics.com

		
	Gnosis:	  	 Gnosis S.p.A.
 Attention to:
Mr. Renzo Berna
 Title: CEO

Address: Via Autobianchi, 1-20832 Desio (MB)

Fax: [**]
 e-mail: [**]

 15.3 Entire Agreement. This Agreement and the Exhibits hereto represent the entire understanding
and agreement of the Parties with respect to the subject matter hereto and supersedes all prior agreements, understandings or arrangements among the Parties with respect to the supply of Product to Durata, including the Transition Services
Agreement. 
 15.4 Waiver-Modification of Agreement. No waiver or modification of any of the terms of this Agreement
shall be valid unless in writing and signed by authorized representatives of both Parties. Failure by either Party to enforce any such rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by either Party
in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances. 
 15.5
Headings; Construction. The Article and Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. In construing this Agreement, unless
expressly specified otherwise; (a) references to Articles, Sections and Exhibits are to articles, sections of, and exhibits to, this Agreement; (b) except where the context otherwise requires, use of either gender includes the other
gender, and use of the singular includes the plural and vice versa; (c) headings and titles are for convenience only and do not affect the interpretation of this Agreement; (d) any list or examples following the word “including”
shall be interpreted without limitation to the generality of the preceding words; (e) except where the context otherwise requires, the word “or” is used in the inclusive sense; (f) all references to “dollars” or
“$” herein shall mean U.S. Dollars; and (g) each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and
applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. Any terms or conditions contained in an invoice that are inconsistent or in conflict
with this Agreement shall be deemed not to be a part of such invoice. 
 145.6 Severability. Should one or several
provisions of this Agreement be or become invalid, then the parties hereto shall substitute such invalid provisions by valid ones, which in their economic effect come so close to the invalid provisions that it can be reasonably assumed that the
parties would have contracted this Agreement also with those new provisions. In case such provisions cannot be found, the invalidity of one or several provisions of this Agreement shall not affect the validity of the Agreement as a whole, unless the
invalid provisions are of such essential importance for this Agreement that it is to be reasonably assumed that the parties would not have contracted this Agreement without the invalid provisions. 

  
 - 17 -

 15.7 Further Assurances. The parties covenant and agree that, subsequent to the
execution and delivery of this Agreement and without any additional consideration, each of the parties shall execute and deliver any further legal instruments and perform such acts which are or may become necessary to effectuate the purposes of this
Agreement. 
 15.8 Relationship of Parties. Nothing contained in or relating to this Agreement shall constitute or be
deemed to constitute a partnership or joint venture among the parties hereto. Neither party nor any of its representatives shall have or hold itself out as having any authority or agency to act on behalf of the other party. 

15.9 Counterparts and Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be
deemed an original, and all of which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail shall be deemed to be original
signatures. 
 IN WITNESS WHEREOF, this Agreement has been executed in two (2) counterparts, as of the Effective Date.

  

					
	Durata Therapeutics, Inc.	 		 	Gnosis S.p.A.
			
	/s/ Corey Fishman	 		 	/s/ Renzo Berna
	 By: Corey Fishman
 Title:
COO
	 		 	 By: Renzo Berna
 Title:
CEO

  
 - 18 -

 Exhibits 

 

			
		
	Exhibit 3.1(i)	 	Product Specifications
		
	Exhibit 3.3(a)	 	Quality Agreement
		
	Exhibit 4.1	 	Minimum annual binding volumes and Supply Price
		
	Exhibit 12.2	 	Dispute Resolution

  
 - 19 -

 EXHIBIT 3.1 

Specifications 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total
of 4 pages were omitted. 
 [**] 

  
 - 20 -

 EXHIBIT 3.3(a) 

QUALITY AGREEMENT 
 Main terms covered in the Quality Agreement, including without limitation: 

Regulatory controls 
 Documentation control 
 Quality 

Material and laboratory control 
 Product processing and release 
 Stability 

  
 - 21 -

 EXHIBIT 4.1 

MINIMUM ANNUAL BINDING VOLUMES AND SUPPLY PRICES 
 The supply prices will be in Euro per kg of Dalbavancin. The prices below will be considered as initial Supply Prices subject to the price adjustment provisions set forth in Section 4.1 and
5.2. The initial supply price for Dalbavancin indicated below will be finalized during the registration batches 

Dalbavancin API Injectable grade: Euro [**] 
 A Development Program will be initiated by Gnosis, to identify potential improvements in the Manufacturing Process. Any change or impact in the Manufacturing Process will be presented to Durata according
to Section 8.1. 
 According to volumes indicated below, supply prices of Dalbavancin are: 

Year 1—2013: at least [**] Kg Euro [**] 
 Year 2 -2014: at least [**] Kg Euro [**] 
 Year 3—2015: at least [**] kg
Euro [**] 
 Year 4—2016: quantities and pricing to be defined by [**] 

Year 5—2017: quantities and pricing to be defined by [**] 
 Gnosis is the Main Supplier for the first [**] years of Product supply [**]. 
 Main Supplier for
the remaining years [**] will be reconfirmed by [**]. 

  
 - 22 -

 EXHIBIT 12.2 

DISPUTE RESOLUTION 

In the event of any dispute arising under this Agreement, a Party shall provide written notice of the dispute to the other Party. In order to resolve the
dispute, the Parties shall follow the procedures set forth in this Exhibit 12.2 to facilitate a resolution. 
  

	 	(a)	Each Party shall designate one senior executive to represent it in a meeting to resolve the dispute. Within [**] days after receipt of written notice of a dispute, the
designated executive officers shall meet, in person or by telephone, to attempt to resolve the dispute. The designated executive officers shall negotiate in good faith to achieve a resolution to the dispute referred to them within [**] days after
such meeting. 

  

	 	(b)	If the designated executive officers are unsuccessful in resolving the dispute as provided in (a), either Party may submit the dispute for resolution through binding
arbitration. 

  

	 	(c)	All disputes, controversies, and claims directly or indirectly arising out of or in relation to this Agreement or the validity, interpretation, construction,
performance, breach or enforceability of this Agreement (each a “Dispute”) not resolved as provided above shall be settled by binding arbitration (“Arbitration”), as provided below, under the International Chamber
of Commerce Rules of Arbitration which are in effect as of the Effective Date (the “Rules”). 

  

	 	(d)	Each Arbitration will be conducted in English and all foreign language documents shall be submitted in the original language and, if so requested by any arbitrator or
Party, shall also be accompanied by a translation into English. The Arbitration proceedings shall take place in London, England, and may be initiated by either Party in accordance with the Rules. The Arbitration shall be administered by the
International Chamber of Commerce, and the governing law set forth in Section 12.1 shall govern any such proceedings. The arbitrator(s) in any Arbitration shall enforce and not modify the terms of this Agreement. The award of the
arbitrator shall be final and binding on each Party and its respective successors and assigns, and judgment may be entered thereupon and enforced in any court of competent jurisdiction pursuant to the United Nations Convention on the Recognition and
Enforcement of Foreign Arbitrator Awards or other applicable law. All costs and expenses of any Arbitration, including reasonable attorneys’ fees and expenses and the administrative and arbitrator fees, shall be borne by the Parties as
determined by the arbitrator. Nothing herein shall be construed as limiting the right of a Party to seek, in a court of competent jurisdiction, an injunction or other equitable relief in aid of arbitration (including to maintain the status quo or
preserve the subject matter of the arbitration) with respect to any actual or threatened breach of this Agreement or otherwise to prevent or avoid irreparable harm. Nothing herein shall permit the arbitrators to award damages that may not be awarded
under Section 14.5. 

  

	 	(e)	Except to the limited extent necessary to comply with applicable law, legal process, with a court order, to enforce a final settlement agreement or to secure
enforcement of, a judgment on, or vacatur of the arbitrator’s award, the Parties agree that the existence, terms and content of any arbitration proceeding entered into pursuant to this Agreement, all information and documents disclosed in
arbitration by either Party or evidencing any arbitration results, award, judgment or settlement, or the performance thereof, and any allegations, statements and admissions made or positions taken by either Party in an arbitration proceeding shall
be treated and maintained in confidence and are not intended to be used or disclosed for any other purpose or in any other forum. 

  
 - 23 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]